Active Pharmaceutical Ingredients
Progestogen and Estrogen | |||
Product Name | Specification | Approved | CAS No. |
Progesterone | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
Pregnenolone |
In-house |
Kosher | 145-13-1 |
Medroxyprogesterone Acetate | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
Megestrol Acetate | CP/EP/USP | DMF in process | 595-33-5 |
Mifepristone | CP/IP | DMF/GMP | 84371-65-3 |
Cyproterone Acetate | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
Levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
Norethisterone |
CP/EP/USP/JP |
DMF in process |
68-22-4 |
Norethisterone Acetate |
EP/USP |
DMF in process |
51-98-9 |
Norethisterone Enanthate |
In-house |
Under R&D |
3836-23-5 |
Drospirenone | EP/USP | DMF | 67392-87-4 |
Gestodene | CP/EP | DMF/GMP | 60282-87-3 |
Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
Estriol | CP/EP/USP | Under R&D | 50-27- 1 |
Ethinyl Estradiol | CP/EP/USP | GMP | 57-63-6 |
Estradiol Valerate | CP/EP/USP/KP | DMF | 979-32-8 |
Estradiol Cypionate |
USP |
DMF in process |
313-06-4 |
Tibolone | CP/EP | DMF/GMP | 5630-53-5 |
Dienogest | EP | CEP/GMP | 65928-58-7 |
Fulvestrant | EP/USP | Under R&D | 129453-61-8 |
Exemestane | CP/EP/USP | Under R&D | 107868-30-4 |
Androgen | |||
Product Name | Specification | Approved | CAS No. |
Finasteride | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
Dutasteride | EP/USP | CEP/FDA | 164656-23-9 |
Abiraterone Acetate | CP/USP | DMF/WC | 154229-18-2 |
Darolutamide |
In-house |
Under R&D |
1297538-32-9 |
Testosterone | CP/EP/USP | CEP/WC/FDA | 58-22-0 |
Testosterone Undecanoate | CP | DMF/WC | 5949-44-0 |
Testosterone Cypionate | USP | Under R&D | 58-20-8 |
Testosterone Enanthate |
USP/JP |
Under R&D |
315-37-7 |
Testosterone Propionate |
CP/EP/USP/JP |
Under R&D |
57-85-2 |
DHEA(Prasterone) | FP/In-house | DMF/WC/Kosher | 53-43-0 |
Clascoterone | In-house | DMF in process | 19608-29-8 |
Cortical Hormone | |||
Product Name | Specification | Approved | CAS No. |
Budesonide | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
Desonide | CP/USP | DMF/GMP | 638-94-8 |
Eplerenone | EP | CEP in process | 107724-20-9 |
Methylprednisolone | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
Methylprednisolone Hemisuccinate | CP/EP/USP | DMF/GMP | 2921-57-5 |
Fluticasone Propionate | CP/EP/USP | DMF | 80474- 14-2 |
Fluticasone Furoate | CP/EP | DMF in process | 397864-44-7 |
Mometasone Furoate |
CP/EP/USP |
DMF in process |
Anhydrous (83919-23-7) Monohydrate (141646-00-6) |
Deflazacort |
In-house |
Under R&D |
14484-47-0 |
Others | |||
Product Name | Specification | Approved | CAS No. |
Oxcarbazepine | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
Eslicarbazepine Acetate | CP/USP | DMF | 236395- 14-5 |
Ganciclovir | CP/EP/USP | DMF/GMP | 82410-32-0 |
Valganciclovir Hydrochloride | USP/EP | CEP in process | 175865-59-5 |
Oseltamivir Phosphate | CP/EP/USP | DMF | 204255- 11-8 |
Baloxavir Marboxil | In-house | Under R&D | 1985606-14-1 |
Revefenacin | In-house | DMF | 864750-70-9 |
Mirabegron | CP/EP | DMF | 223673-61-8 |
Vibegron |
In-house |
Under R&D |
1190389-15-1 |
Escitalopram Oxalate | CP/EP/USP | DMF in process | 219861-08-2 |
Citalopram Hydrobromide |
CP/EP/USP |
DMF in process |
59729-32-7 |
Cariprazine Hydrochloride | In-house | DMF | 1083076-69-0 |
Lasmiditan Succinate | In-house | DMF | 439239-92-6 |
Luliconazole | In-house | DMF | 187164-19-8 |
Apalutamide | In-house | DMF | 956104-40-8 |
Tadalafil | CP/EP/USP | Under R&D | 171596-29-5 |
Relugolix | In-house | DMF in process | 737789-87-6 |
Ruxolitinib phosphate |
In-house |
DMF in process |
1092939-17-7 |
Abemaciclib |
In-house |
Under R&D |
1231929-97-7 |
Phloroglucinol | CP/EP | DMF | 108-73-6 |
1,3,5-Trimethoxybenzene |
CP/In-house |
GMP |
621-23-8 |
Ursodeoxycholic Acid | EP/USP/JP | Under R&D | 128-13-2 |
Tauroursodeoxycholic Acid |
In-house |
Under R&D |
14605-22-2 |
Cholesterol |
CP/EP/USP/JP |
Under R&D |
57-88-5 |
Omega-3-Acid Ethyl Ethers 90 |
EP/USP |
DMF in process |
—— |
Medium-Chain Triglycerides |
CP/USP/EP |
DMF |
—— |
Benzalkonium Chloride |
USP/EP/JP |
CEP in process |
8001-54-5 |
Olive Oil (For Injection) |
CP/USP/EP/JP |
DMF in process |
8001-25-0 |
Egg phospholipids (For Injection) |
CP/USP/EP |
DMF |
93685-90-6 |
SNAC |
In-house |
DMF in process |
203787-91-1 |
Estradiol Valerate has CP specification. DMF approved.
Megestrol acetate has CP, EP and USP specifications. DMF under filing.
Eplerenone has EP specifications. CEP available and FDA approved.
Fluticasone propionate has CP, EP and USP specifications. DMF available.